After A Year's Wait, Fed. Circ. Simply OKs Biogen's PTAB Loss
The Federal Circuit on Wednesday affirmed a Patent Trial and Appeal Board ruling that a patent covering Biogen's cancer drug Rituxan is invalid, but didn't address a thornier standing issue that...To view the full article, register now.
Already a subscriber? Click here to view full article